Content deleted Content added
←Created page with '{{infobox drug | drug_name = Fluorothiazinone | image = Fluorothiazinone_structure.png | legal_UK = | legal_DE = | legal_status = Investigational | C = 19 | H = 17 | F = 2 | N = 3 | O = 4 | S = 1 | IUPAC_name = N-(2,4-difluorophenyl)-4-[(3-ethoxy-4-hydroxyphenyl)methyl]-5-oxo-1,3,4-thiadiazine-2-carboxamide <!-- Identifiers --> | CAS_number = 1370706-59-4 | CAS_supplemental = | PubChem = 132512026 | PubChemSubstance = | IUPHAR_lig...' |
No edit summary |
||
Line 27:
}}
'''Fluorothiazinone''' ('''CL-55''', '''Ftortiazinon''') is an [[antibiotic]] drug, first developed in Russia in 2010 and active against various species of [[Gram-negative bacteria]] through inhibition of the [[type III secretion system]] (T3SS). It has seen limited clinical use in Russia and is in clinical trials which may eventually see it accepted for use more widely.<ref>Nesterenko LN, Zigangirova NA, Zayakin ES, Luyksaar SI, Kobets NV, Balunets DV, Shabalina LA, Bolshakova TN, Dobrynina OY, Gintsburg AL. A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo. ''J Antibiot (Tokyo)''. 2016 Jun;69(6):422-7. {{doi|10.1038/ja.2015.131}} {{pmid|26732253}}</ref><ref>Zigangirova NA, Kost EA, Didenko LV, Kapotina LN, Zayakin ES, Luyksaar SI, Morgunova EY, Fedina ED, Artyukhova OA, Samorodov AV, Kobets NV. A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones inhibits intracellular growth and persistence of Chlamydia trachomatis. ''J Med Microbiol''. 2016 Jan;65(1):91-98. {{doi|10.1099/jmm.0.000189}} {{pmid|26489840}}</ref><ref>Provenzani A, Hospodar AR, Meyer AL, Leonardi Vinci D, Hwang EY, Butrus CM, Polidori P. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents. ''Int J Clin Pharm''. 2020 Aug;42(4):1016-1025. {{doi|10.1007/s11096-020-01089-y}} {{pmid|32638294}}</ref><ref>Zigangirova NA, Nesterenko LN, Sheremet AB, Soloveva AV, Luyksaar SI, Zayakin ES, Balunets DV, Gintsburg AL. Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice. ''J Antibiot (Tokyo)''. 2021 Apr;74(4):244-254. {{doi|10.1038/s41429-020-00396-w}} {{pmid|33479520}}</ref><ref>Bondareva NE, Soloveva AV, Sheremet AB, Koroleva EA, Kapotina LN, Morgunova EY, Luyksaar SI, Zayakin ES, Zigangirova NA. Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in mice. ''J Antibiot (Tokyo)''. 2022 Mar;75(3):155-163. {{doi|10.1038/s41429-022-00504-y}} {{pmid|35064243}}</ref><ref>Reig S, Le Gouellec A, Bleves S. What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert? ''Front Cell Infect Microbiol''. 2022 Jul 8;12:909731. {{doi|10.3389/fcimb.2022.909731}} {{pmid|35880080}}</ref><ref>Koroleva EA, Soloveva AV, Morgunova EY, Kapotina LN, Luyksaar SI, Luyksaar SV, Bondareva NE, Nelubina SA, Lubenec NL, Zigangirova NA, Gintsburg AL. Fluorothiazinon inhibits the virulence factors of uropathogenic Escherichia coli involved in the development of urinary tract infection. ''J Antibiot (Tokyo)''. 2023 May;76(5):279-290. {{doi|10.1038/s41429-023-00602-5}} {{pmid|36922636}}</ref><ref>Tsarenko SV, Zigangirova NA, Soloveva AV, Bondareva NE, Koroleva EA, Sheremet AB, Kapotina LN, Shevlyagina NV, Andreevskaya SG, Zhukhovitsky VG, Filimonova EV, Gintsburg AL. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia. ''J Antibiot (Tokyo)''. 2023 Jul;76(7):397-405. {{doi|10.1038/s41429-023-00621-2}} {{pmid|37085670}}</ref><ref>[https://hij.ru/read/31227/ От пенициллина — к фтортиазинону]</ref>
== See also ==
| |||